App aims to outsmart heart disease: digital coach tested in 790 patients
NCT ID NCT07332468
First seen Jun 27, 2026 · Last updated Aug 20, 2026 · Updated 2 times
Summary
This study tests whether a smartphone app that helps manage blood pressure, cholesterol, and blood sugar can lower heart disease risk better than standard care. About 790 adults at high risk for heart disease will use the app for one year, with doctors reviewing its suggestions. The goal is to see if digital coaching leads to better long-term heart health.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- smartphone-based digital remote management platform
- What this could lead to
- If successful, this could show that a smartphone app helps people better manage heart disease risk factors like blood pressure and cholesterol.
- What could go wrong
- This is an early-stage trial with 790 participants, and the app's suggestions still need doctor approval, so results may not apply broadly or show clear benefit over usual care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 564 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Apr 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
35 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. 10-year ASCVD risk ≥ 10%, calculated using the China-PAR risk prediction model 2. Adultd aged ≥ 35 years 3. Able to use a smartphone (or assisted by family) and agrees to remote management 4. Signed informed consent Exclusion Criteria: 1. History of acute myocardial infarction, stroke, heart failure, malignant arrhythmia, or prior percutaneous coronary intervention or coronary artery bypass grafting surgery 2. Moderate to severe hepatic dysfunction (Child-Pugh class B-C) 3. CKD stages 4-5 (eGFR \<30 ml/min/1.73m²) or on dialysis 4. Chronic obstructive pulmonary disease requiring ongoing home oxygen therapy or chronic oral steroid therapy as an outpatient 5. Pregnant, planning to become pregnant within the next 12 months 6. Life expectancy \<12 months (e.g., advanced malignancy, etc.); 7. Cognitive impairment or communication disorder.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atherosclerotic cardiovascular diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
5 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Beijing Anzhen Hospital, Capital Medical University, Beijing, China
RECRUITINGBeijing, China
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
RECRUITINGShanghai, China
-
The First Affiliated Hospital of Dalian Medical University, Dalian, China
RECRUITINGDalian, China
-
The First Hospital of Jilin University, Changchun, China
RECRUITINGChangchun, China
-
The Second Affiliated Hospital of Nanchang University, Nanchang, China
RECRUITINGNanchang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.